InvestorsHub Logo
Followers 3
Posts 190
Boards Moderated 0
Alias Born 05/16/2013

Re: None

Monday, 07/14/2014 2:10:43 PM

Monday, July 14, 2014 2:10:43 PM

Post# of 426546
JL, much respect here, too. I look forward to all of your posts. However, my first point was about fiduciary responsibility to uphold shareholder value (and there may be meaningful value there - not much but something), and my second point about impact of a pro-Amarin NCE decision on FDA's approach to handling the SPA controversy. For instance, NCE proceedings may shine additional light on FDA's procedural flaws related to Vascepa. I agree - NCE is minor and not intrinsically tied to SPA, but there may still be management issues at stake for both AMRN and FDA here that compel the NCE suit.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News